Melanotan II

Melanotan II MC1R Research: Melanogenesis Pathway Studies in Melanocyte Cell Models Melanotan II represents a synthetic analog of α-melanocyte stimulating hormone (α-MSH) extensively studied in cell-based assay formats for its broad melanocortin receptor (MC1R, MC3R, MC4R, MC5R) binding and cAMP signaling. Published in vitro research characterizes its molecular interactions, binding affinity profiles, and downstream pathway engagement in defined cell model systems under controlled laboratory conditions. Receptor Pharmacology and Mechanism of Action Melanotan II demonstrates agonist activity at multiple melanocortin receptor subtypes through direct receptor binding and subsequent G-protein coupled receptor (GPCR) activation. The compound exhibits particularly high binding affinity for MC1R expressed in melanocyte cell lines, with Ki values in the nanomolar range according to radioligand displacement assays. Comparative binding studies reveal differential receptor selectivity profiles across melanocortin receptor subtypes, with MC1R and MC4R showing enhanced binding kinetics relative to MC3R and MC5R in heterologous expression systems. The primary signaling mechanism involves adenylyl cyclase activation following receptor occupancy, resulting in elevated intracellular cyclic adenosine monophosphate (cAMP) concentrations. Fluorescence-based cAMP accumulation assays demonstrate dose-dependent responses in transfected cell models, with EC50 values typically ranging from 0.1-10 nM depending on receptor subtype and cellular expression levels. Melanogenesis Pathway Activation cAMP-PKA Signaling Cascade Following MC1R activation in melanocyte cell models, elevated cAMP levels trigger protein kinase A (PKA) phosphorylation events that propagate melanogenesis signaling. In vitro kinase assays demonstrate PKA-mediated phosphorylation of cAMP response element-binding protein (CREB) at serine-133, facilitating transcriptional activation of melanogenic enzymes. Time-course studies in B16 melanoma cell lines reveal peak CREB phosphorylation occurring 15-30 minutes post-treatment, correlating with downstream gene expression changes. Tyrosinase Expression and Activity Melanotan II treatment in melanocyte cell cultures induces significant upregulation of tyrosinase, the rate-limiting enzyme in melanin biosynthesis. Quantitative PCR analysis demonstrates 3-8 fold increases in tyrosinase mRNA expression within 6-12 hours of receptor activation. Western blot analysis confirms corresponding protein level increases, with peak tyrosinase expression occurring 24-48 hours post-treatment in immortalized melanocyte cell lines. Enzymatic activity assays measuring L-DOPA oxidation reveal enhanced tyrosinase catalytic function following Melanotan II exposure. Spectrophotometric analysis of dopachrome formation demonstrates dose-dependent increases in enzyme activity, with maximal stimulation occurring at concentrations corresponding to receptor saturation in binding studies. Comparative Receptor Binding Studies Melanocortin Receptor Selectivity Competition binding experiments utilizing radiolabeled α-MSH reveal distinct binding profiles for Melanotan II across melanocortin receptor subtypes. Scatchard analysis in CHO cells expressing individual receptor subtypes demonstrates highest affinity binding at MC1R (Ki ~0.2 nM) and MC4R (Ki ~0.5 nM), with reduced affinity at MC3R (Ki ~2.1 nM) and MC5R (Ki ~1.8 nM) under standard assay conditions. Structure-activity relationship studies comparing Melanotan II with endogenous α-MSH reveal enhanced receptor binding stability due to cyclization and D-amino acid substitutions. These modifications confer resistance to peptidase degradation while maintaining receptor activation potency in cell-based functional assays. Downstream Signaling Pathways MITF Transcriptional Regulation MC1R activation triggers microphthalmia-associated transcription factor (MITF) upregulation through PKA-mediated phosphorylation events. Immunofluorescence microscopy in cultured melanocytes demonstrates nuclear MITF accumulation following Melanotan II treatment, with quantitative analysis revealing 4-6 fold increases in nuclear fluorescence intensity. Chromatin immunoprecipitation assays confirm enhanced MITF binding to tyrosinase gene promoter sequences, establishing the transcriptional mechanism underlying melanogenic enzyme induction. Melanin Synthesis Quantification Direct melanin content analysis in Melanotan II-treated cell cultures employs spectrophotometric measurement following sodium hydroxide extraction. Dose-response studies demonstrate concentration-dependent melanin accumulation with saturable kinetics, reaching plateau levels at 10-100 nM depending on cell line characteristics and culture duration. High-performance liquid chromatography analysis distinguishes eumelanin and pheomelanin production ratios, revealing preferential eumelanin synthesis in MC1R-expressing cell models. Research Summary In vitro pharmacological characterization of Melanotan II demonstrates potent melanocortin receptor agonist activity with particular selectivity for MC1R subtypes. The compound effectively activates cAMP-PKA signaling cascades leading to CREB phosphorylation, MITF upregulation, and subsequent tyrosinase expression increases. Quantitative analysis of melanogenesis endpoints confirms robust melanin synthesis stimulation in appropriate cell model systems. These receptor-mediated effects establish Melanotan II as a valuable research tool for investigating melanocortin signaling pathways and melanogenic regulatory mechanisms in controlled laboratory environments. All content is intended for in vitro laboratory research purposes only. Not for human or animal consumption. Not intended to diagnose, treat, cure, or prevent any condition. Hexarelin TB-500 Epithalon Ipamorelin Tirzepatide CJC-1295 DAC PT-141 Semaglutide Selank BPC-157 Sermorelin Melanotan 2 IGF LR3 Tesamorelin AICAR IGF-DES GHRP 2 Albuterol Tamoxifen Letrozole Clomiphene Tadalafil Clenbuterol Anastrozole Finasteride Exemestane Sildenafil Yohimbine Bacteriostatic Water Recent Posts Melanotan 2 (MT2): Mechanism, Research, and Safety Considerations Ipamorelin: The Selective GHRP, Explained Tesamorelin: The GHRH Analog Studied for Visceral Fat Sermorelin: The Original GHRH Analog, Explained CJC-1295: How the GHRH Analog Works, and What Research Shows Already a customer? Sign In Create Account All products on this site are for Research, Development use only. Products are Not for Human consumption of any kind. The statements made within this website have not been evaluated by the US Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure or prevent any disease. ElementSarms is a chemical supplier. ElementSarms is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic act. ElementSarms is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic act. Sarms Stacks Research Liquids Albuterol 5MG/ML | 30ML with dropper Anastrozole 1.5MG/ML | 30ML with dropper Clomiphene 50MG/ML | 30ML with dropper Finasteride 5MG/ML | 30ML with dropper Letrozole 3.5 MG/ML | 30ML with dropper LiquiCia 30MG/ML | 30ML with dropper LiquiCia T50 50MG/ML | 30ML with dropper LiquiClen 200MCG/ML | 30ML with dropper Liquistane / Exemestane 25MG/ML | 30ML with dropper LiquiTamo 20MG/ML | 30ML with dropper LiquiVia 25MG/ML | 30 ML with dropper T3 LIOTHYRONINE 200MCG/ML | 30ML with dropper Toremifene Citrate 60MG/ML | 30ML with dropper Yohimbine HCL 10MG/ML | 30ML with dropper Research Peptides Aicar 50MG BPC-157 + TB-500 Blend 2mg ea/ 4MG BPC-157 5MG CJC-1295 + DAC 2MG CJC-1295 | No DAC 2MG Epithalon 10MG Frag Premium 176-191 5MG GHK-CU Copper Peptide 50MG GHRP-2 5MG GHRP-6 5MG Hexarelin 5MG IGF-1 DES 1MG IGF-1 LR3 1MG Ipamorelin 5MG Melanotan 2 10MG NAD+ 500MG PT-141 / Bremelanotide 10MG GLP-1/GIP/GCG (RT) Selank 5MG GLP1 (SM) Sermorelin 5MG TB-500 5MG GIP/GLP-1 (TZ) PDE5 Inhibitors GLP-1 Diluents Bacteriostatic Water 10ML

Every part of the MT-II erectile story has to be read against a large gap between mechanistic plausibility and clinical proof. It is easy to be impressed by the coherence of the mechanism, the central MC4R pathway, the PVN-oxytocin-spinal circuit, the dopaminergic arousal component, and to slide into treating that as evidence of clinical benefit. It is not. Mechanistic plausibility is a hypothesis-generator, not a demonstration that a compound helps real patients safely.1,8 The first limitation is the sheer smallness and age of the human data. The pivotal erectile studies involved roughly ten to twenty men and were published in 1996, 1998, and 2000. In the decades since, MT-II itself has not been advanced through the large, modern, randomized controlled trials that define efficacy and safety for an approved therapy. When a compound shows an early signal and then is not developed further, that absence is informative: it often reflects tolerability problems, commercial decisions to pursue a cleaner derivative, or both. Here it reflects both, since the field moved to the more selective bremelanotide.3,12 The second limitation is population and generalizability. The early studies enrolled specific groups (initially psychogenic ED, then some organic ED) in tightly controlled settings. They tell us little about durability of effect, repeat dosing over months, interactions with common medications, or effects in the older men and men with cardiovascular and metabolic disease who make up much of the real erectile-dysfunction population. The dopaminergic and central mechanism also raises unanswered questions about tolerance and receptor desensitization with repeated use that the short studies could not address.8,11 The third limitation is translational. Much of the mechanistic confidence rests on rodent studies. Rat erectile neurophysiology is a reasonable model, but species differences in receptor distribution, dosing, and behavior mean rodent results cannot be assumed to hold quantitatively in humans. The most human-relevant mechanistic claim, that melanocortin agonists initiate erection centrally and independently of PDE5, is supported by the human observation of erections without stimulation, but the finer details of the human circuit are extrapolated from animals.9,10 The fourth and most practically important limitation is the disconnect between the studied compound and the marketed one. Everything published used defined, pharmaceutical-grade peptide at controlled doses. The MT-II available to consumers is an unregulated chemical of uncertain identity, purity, and concentration, self-dosed without monitoring. Independent analyses have found gray-market vials whose measured peptide content diverged notably from the label. This means the already-limited clinical inferences are further eroded in the real world: a user is not reproducing the conditions of the studies, and cannot know what they are actually taking. The net conclusion is that the honest evidence status of MT-II for erectile performance is “biologically plausible, preliminarily suggested in small old studies, and unproven and unapproved as a therapy.”2,15